Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

Grade 3 and 4 adverse events (AEs) during cycle 1 are traditionally used for dose escalation decisions in Phase I oncology trials. With molecularly targeted agents (MTAs), assessment of lower grade AEs and those in later cycles is considered increasingly relevant. We conducted a retrospective analys...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2018-09, Vol.9 (74), p.33961-33971
Hauptverfasser:	Jordan, Emma J, Spicer, James, Sarker, Debashis
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!